Results 281 to 290 of about 62,912 (312)

Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial

American Journal of Gastroenterology, 2023
INTRODUCTION: Intravenous corticosteroids are the mainstay of treatment of patients hospitalized with acute severe ulcerative colitis (ASUC). However, 30%–40% of the patients are refractory to corticosteroids.
Arshdeep Singh, M. Goyal, V. Midha, R. Mahajan, K. Kaur, Y. Gupta, Dharmatma Singh, N. Bansal, Ramandeep Kaur, Shivam Kalra, O. Goyal, V. Mehta, A. Sood   +12 more
semanticscholar   +1 more source

Tofacitinib for acute severe ulcerative colitis: a systematic review.

Journal of Crohn's & Colitis, 2023
BACKGROUND Tofacitinib has emerged as a new potential treatment for acute severe ulcerative colitis (ASUC). We conducted a systematic review to assess efficacy, safety, and integration in ASUC algorithms.
C. Steenholdt, P. Ovesen, J. Brynskov, J. Seidelin   +3 more
semanticscholar   +1 more source

Regulation of fibronectin and collagens type I, III and VI by TNF-α, TGF-β, IL-13, and tofacitinib

Scientific Reports
Understanding how inflammatory cytokines influence profibrogenic wound healing responses in fibroblasts is important for understanding the pathogenesis of fibrosis.
F. Gillesberg, M. Pehrsson, A. Bay‐Jensen, Peder Frederiksen, Morten A Karsdal, B. Deleuran, T. Kragstrup, S. Kubo, Yoshiya Tanaka, Joachim H. Mortensen   +9 more
semanticscholar   +1 more source

Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis.

Inflammatory Bowel Diseases, 2021
BACKGROUND Knowledge of the real-world effectiveness and safety of tofacitinib for ulcerative colitis (UC) is relevant to confirm the benefit observed in clinical trials.
C. Taxonera, D. Olivares, C. Alba
semanticscholar   +1 more source

Comparative Effectiveness of Upadacitinib and Tofacitinib in Ulcerative Colitis: A US Propensity-Matched Cohort Study

American Journal of Gastroenterology
INTRODUCTION: There are limited real-world data comparing the effectiveness of upadacitinib and tofacitinib in patients with ulcerative colitis (UC). METHODS: We conducted a retrospective cohort study using TriNetX, a multi-institutional database, to ...
G. Kochhar, Himsikhar Khataniar, V. Jairath, F. Farraye, Aakash Desai   +4 more
semanticscholar   +1 more source

Tofacitinib versus oral prednisolone for induction of remission in moderately active ulcerative colitis (ORCHID): A prospective, open-label, randomized, pilot study.

Journal of Crohn's & Colitis, 2023
BACKGROUND Oral corticosteroids are first line agents to induce remission in moderately active ulcerative colitis (UC), but are associated with adverse effects.
Ashutosh Kumar Singh, V. Midha, K. Kaur, R. Mahajan, Dharmatma Singh, Ramandeep Kaur, Aditya Kohli, Avantika Chawla, K. Sood, N. Bansal, A. Sood   +10 more
semanticscholar   +1 more source

One-Year Comparative Effectiveness of Upadacitinib vs Tofacitinib for Ulcerative Colitis: A Multicenter Cohort Study

American Journal of Gastroenterology
INTRODUCTION: The comparative effectiveness of upadacitinib and tofacitinib for ulcerative colitis (UC) is poorly understood. METHODS: In this retrospective cohort study, we compared steroid-free clinical remission (SFCR) and endoscopic response ...
Rahul S. Dalal, Govind H Kallumkal, Heidy J. Cabral, Edward L. Barnes, J. Allegretti   +4 more
semanticscholar   +1 more source

Tofacitinib therapy in refractory inflammatory myositis: a retrospective cohort study of 41 patients.

Rheumatology, 2023
OBJECTIVES To evaluate the efficacy and safety of tofacitinib in treatment-refractory inflammatory myositis in a real-world clinical setting. METHODS All patients with refractory inflammatory myositis treated with tofacitinib from a single urban center
Madelaine Beckett, Julia Tan, Evelyne Bonnardeaux, J. Dutz, K. Shojania, F. To, Anthony Obrzut, J. Aviña-Zubieta, Kun Huang   +8 more
semanticscholar   +1 more source

Tofacitinib in Pediatric Ulcerative Colitis: A Retrospective Multicenter Experience.

Inflammatory Bowel Diseases
BACKGROUND Tofacitinib has recently been approved for treatment of moderate-to-severe ulcerative colitis (UC) in adults, yet pediatric data are limited.
O. Ledder, M. Dolinger, Marla C. Dubinsky, R. Stein, Srisindu Vellanki, Rachel Buckuk, Ayesha Fatima, D. Suskind, J. Scarlett, Dennis Röser, D. Shouval, Gabriele Meyer, Zarela Molle Rios, G. Pujol-Muncunill, A. Lozano, K. Kolho, P. Rohani, S. Hussey, T. de Mejj, Travis Ayers, V. Navas-López, Dan Turner, C. Tzivinikos   +22 more
semanticscholar   +1 more source